CMO Carmen Bozic (Vertex)
Vertex shares take a hit as liver tox forces the research team to scrap a PhII drug for AAT patients. Will we see new deals now?
Vertex is taking the ax to one of their rare disease drugs after evidence of liver damage emerged in a key Phase II study that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
